Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDX Ardelyx	$6.37 +2.8%	$4.73	$3.21 ▼ $7.18	$1.53B	0.68	4.71 million shs	2.22 million shs
AVDL Avadel Pharmaceuticals	$14.68 -1.3%	$11.22	$6.38 ▼ $16.66	$1.42B	1.47	1.34 million shs	571,411 shs
GTHX G1 Therapeutics	$7.15	$7.13	$1.08 ▼ $7.19	$373.81M	1.66	1.70 million shs	N/A
SDGR Schrodinger	$19.76 -0.2%	$20.58	$16.60 ▼ $28.47	$1.45B	1.67	1.16 million shs	277,670 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDX Ardelyx	-0.16%	+3.34%	+44.63%	+53.60%	-0.48%
AVDL Avadel Pharmaceuticals	+0.13%	+4.35%	+37.30%	+61.28%	-5.89%
GTHX G1 Therapeutics	0.00%	0.00%	0.00%	0.00%	+0.28%
SDGR Schrodinger	+0.76%	+2.22%	-11.61%	-7.70%	-4.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARDX Ardelyx	4.1399 of 5 stars	3.5	2.0	0.0	4.4	2.1	2.5	0.6
AVDL Avadel Pharmaceuticals	2.7194 of 5 stars	3.6	3.0	0.0	0.0	2.2	1.7	0.6
GTHX G1 Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	2.8535 of 5 stars	3.3	3.0	0.0	0.0	1.7	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDX Ardelyx	3.00	Buy	$11.50	80.68% Upside
AVDL Avadel Pharmaceuticals	3.14	Buy	$19.67	33.95% Upside
GTHX G1 Therapeutics	0.00	N/A	N/A	N/A
SDGR Schrodinger	2.67	Moderate Buy	$27.83	40.89% Upside

Current Analyst Ratings Breakdown

Latest GTHX, ARDX, AVDL, and SDGR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	AVDL Avadel Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $20.00
8/18/2025	SDGR Schrodinger	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$28.00 ➝ $19.00
8/15/2025	SDGR Schrodinger	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$35.00 ➝ $20.00
8/14/2025	SDGR Schrodinger	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
8/14/2025	SDGR Schrodinger	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
8/8/2025	AVDL Avadel Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/8/2025	AVDL Avadel Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/8/2025	AVDL Avadel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $24.00
8/6/2025	ARDX Ardelyx	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$8.00 ➝ $9.00
8/5/2025	ARDX Ardelyx	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$12.00
8/5/2025	ARDX Ardelyx	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $12.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDX Ardelyx	$386.15M	3.97	N/A	N/A	$0.58 per share	10.97
AVDL Avadel Pharmaceuticals	$169.12M	8.43	N/A	N/A	$0.93 per share	15.79
GTHX G1 Therapeutics	$58.20M	6.42	N/A	N/A	$0.68 per share	10.51
SDGR Schrodinger	$207.54M	7.01	N/A	N/A	$4.66 per share	4.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDX Ardelyx	-$39.14M	-$0.23	N/A	20.53	N/A	-14.60%	-36.57%	-13.42%	10/30/2025 (Estimated)
AVDL Avadel Pharmaceuticals	-$48.83M	-$0.03	N/A	244.70	N/A	-1.32%	-3.73%	-1.73%	11/11/2025 (Estimated)
GTHX G1 Therapeutics	-$47.97M	-$0.62	N/A	N/A	N/A	-76.93%	-136.98%	-39.33%	N/A
SDGR Schrodinger	-$187.12M	-$2.48	N/A	N/A	N/A	-76.22%	-45.70%	-24.81%	11/11/2025 (Estimated)

Latest GTHX, ARDX, AVDL, and SDGR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	AVDL Avadel Pharmaceuticals	$0.02	$0.10	+$0.08	$0.10	$60.28 million	$68.13 million
8/6/2025	Q2 2025	SDGR Schrodinger	-$0.83	-$0.59	+$0.24	-$0.59	$52.03 million	$54.76 million
8/4/2025	Q2 2025	ARDX Ardelyx	-$0.13	-$0.08	+$0.05	-$0.08	$82.69 million	$97.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GTHX G1 Therapeutics	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDX Ardelyx	1.44	4.30	4.03
AVDL Avadel Pharmaceuticals	N/A	2.79	2.38
GTHX G1 Therapeutics	1.34	2.48	2.12
SDGR Schrodinger	N/A	3.30	3.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDX Ardelyx	58.92%
AVDL Avadel Pharmaceuticals	69.19%
GTHX G1 Therapeutics	24.21%
SDGR Schrodinger	79.05%

Insider Ownership

Company	Insider Ownership
ARDX Ardelyx	4.80%
AVDL Avadel Pharmaceuticals	5.20%
GTHX G1 Therapeutics	6.11%
SDGR Schrodinger	21.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDX Ardelyx	90	240.98 million	229.42 million	Optionable
AVDL Avadel Pharmaceuticals	70	97.10 million	92.05 million	Optionable
GTHX G1 Therapeutics	170	52.28 million	49.09 million	Optionable
SDGR Schrodinger	790	73.61 million	58.15 million	Optionable

GTHX, ARDX, AVDL, and SDGR Headlines

Recent News About These Companies

Deutsche Bank AG Sells 188,717 Shares of Schrodinger, Inc. $SDGR

August 27 at 3:29 AM | marketbeat.com

American Century Companies Inc. Invests $19.79 Million in Schrodinger, Inc. $SDGR

August 26 at 3:50 AM | marketbeat.com

Schrodinger, Inc. $SDGR Shares Sold by Vanguard Group Inc.

August 24, 2025 | marketbeat.com

Schrödinger: A Complex Story With Many Moving Parts

August 21, 2025 | seekingalpha.com

Public Sector Pension Investment Board Raises Stake in Schrodinger, Inc. $SDGR

August 21, 2025 | marketbeat.com

Cetera Investment Advisers Takes Position in Schrodinger, Inc. $SDGR

August 21, 2025 | marketbeat.com

Morgan Stanley Cuts Schrodinger (NASDAQ:SDGR) Price Target to $19.00

August 20, 2025 | marketbeat.com

Morgan Stanley Issues Pessimistic Forecast for Schrodinger (NASDAQ:SDGR) Stock Price

August 20, 2025 | americanbankingnews.com

What 4 Analyst Ratings Have To Say About Schrodinger

August 18, 2025 | benzinga.com

Tocqueville Asset Management L.P. Sells 23,590 Shares of Schrodinger, Inc. (NASDAQ:SDGR)

August 18, 2025 | marketbeat.com

Schrodinger, Inc. (NASDAQ:SDGR) Receives $31.20 Consensus Price Target from Analysts

August 18, 2025 | americanbankingnews.com

Schrodinger (NASDAQ:SDGR) Shares Gap Down - Should You Sell?

August 17, 2025 | marketbeat.com

Schrodinger (NASDAQ:SDGR) Upgraded to Strong-Buy at Barclays

August 17, 2025 | marketbeat.com

Tejara Capital Ltd Has $2.65 Million Holdings in Schrodinger, Inc. (NASDAQ:SDGR)

August 17, 2025 | marketbeat.com

Schrodinger (NASDAQ:SDGR) Shares Gap Down - Time to Sell?

August 17, 2025 | americanbankingnews.com

Schrodinger (NASDAQ:SDGR) Earns Overweight Rating from Analysts at Barclays

August 17, 2025 | americanbankingnews.com

Schrodinger (SDGR) Gets a Buy from Barclays

August 16, 2025 | theglobeandmail.com

Craig-Hallum Sticks to Its Buy Rating for Schrodinger (SDGR)

August 16, 2025 | theglobeandmail.com

Schrodinger (NASDAQ:SDGR) Sets New 12-Month Low - Here's What Happened

August 16, 2025 | marketbeat.com

Schrodinger downgraded at Citi after clinical program exit

August 16, 2025 | msn.com

Citigroup Downgrades Schrödinger (SDGR)

August 16, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GTHX, ARDX, AVDL, and SDGR Company Descriptions

Ardelyx NASDAQ:ARDX

$6.36 +0.18 (+2.83%)

As of 03:51 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Avadel Pharmaceuticals NASDAQ:AVDL

$14.68 -0.19 (-1.26%)

As of 03:52 PM Eastern

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

G1 Therapeutics NASDAQ:GTHX

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Schrodinger NASDAQ:SDGR

$19.76 -0.04 (-0.18%)

As of 03:51 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time